logo
‘Landmark study' led by UNLV shows new path to treat, prevent autism

‘Landmark study' led by UNLV shows new path to treat, prevent autism

Miami Herald06-05-2025

National 'Landmark study' led by UNLV shows new path to treat, prevent autism
Dr. Lukasz Sznajder sets up the polymerase chain reaction to detect RNA changes with the assistance of lab students as part of the Sznajder genetics lab at UNLV on April 30, 2025, in Las Vegas. From left, Daniela Hernandez Ensenat, Marcella Siqueira, Manisha Gun, Sznajder and Lil Costello. (L.E. Baskow/Las Vegas Review-Journal/TNS)
TNS
LAS VEGAS - A UNLV-led study has discovered a new molecular path that leads to autism, potentially opening the way for more intervention in the future.
The study by Łukasz Sznajder, a UNLV chemistry and biochemistry professor, was published on April 21 in the journal Nature Neuroscience.
It found that a gene that causes myotonic dystrophy - a genetic condition that creates progressive muscle weakness - also causes autism spectrum disorder. Researchers say the study can help with new diagnoses, prevention and treatment of autism.
"This is a landmark example of an RNA-mediated pathway to autism. It doesn't account for all of autism, but it exposes one route among the many that lead to the spectrum," Ryan Sultan, a psychiatrist and research director at Integrative Psych and a clinical psychiatry assistant professor at Columbia University.
Link between autism and myotonic dystrophy
Around 95% of children with autism have at least one extra condition, Sznajder said.
As a geneticist, Sznajder had long noticed a high crossover between people suffering from myotonic dystrophy and autism.
So, he posed the question: "What is happening in the brains of people with myotonic dystrophy on the molecular level, and what is happening in the brains of people with autism?"
Joined by researchers at the University of Florida as well as in Poland and Toronto, the team found that changes in the DMPK gene that cause myotonic dystrophy also cause autism-related genes to be "mis-spliced," so multiple autism-related genes work differently. When mutated DMPK RNAs are created, they act as a sponge and absorb otherwise healthy proteins from the muscleblind-like (MBNL) family of genes - disrupting muscle and brain development.
"Many people with myotonic dystrophy also have autism, but it wasn't clear why. Here, the scientists have found the mechanism for this - the DMPK gene regulates known autism risk genes that are important for nervous system function," Audrey Brumback, an assistant professor of neurology and pediatrics at the University of Texas at Austin, said.
Brumback said it is important because it has the potential to develop treatments that target mis-splicing so that the healthy versions of the proteins are produced.
Autism genetic
Ample research shows that autism is a genetic disorder - it is around 60% to 90% genetics, which leaves some room for environmental factors.
The research, however, has been far less conclusive on what those genes and mutations are, Sznajder said. Different studies have shown a "laundry list" of genes that may contribute to autism.
"The message is that autism can sometimes arise from changes not in the DNA sequence of an autism gene, but in how that gene's information is sliced and diced in the brain. It's a more nuanced genetic influence - one that was invisible to us until techniques like RNA sequencing revealed it," Sultan said.
But despite the overwhelming research indicating autism is primarily genetic, the issue has become increasingly contentious.
Department of Health and Human Services Secretary Robert F. Kennedy Jr. has discounted the genetic causes of autism and has said that it is from an "environmental toxin."
Before becoming head of the department, Kennedy joined anti-vaccine advocates in claiming childhood vaccines are responsible for autism, but studies by the CDC and others have ruled that out, according to The Associated Press. A fraudulent study claiming a link to the measles, mumps and rubella vaccine was later retracted by the journal that published it, the AP said.
The Autism Society of America called Kennedy's statements "harmful, misleading and unrealistic."
"Autism is a complex developmental disability shaped by genetic, biological, and environmental factors. It is neither a chronic illness nor a contagion, that qualifies harmful language like "epidemic," and to do so is both inaccurate and stigmatizing," the organization said in a statement.
'Connecting the dots'
That makes Sznajder's research, he said, all the more important.
Sznajder hopes the research will help design new diagnostic tools and screen children with myotonic dystrophy for autism, and vice versa. He also said that clinical trials for myotonic dystrophy could be used for treatment or prevention of autism.
"It's exactly connecting those dots," Sznajder said. "As we understand the linkage between gene and autism, now we can think about intervention."
It also opens questions for whether it can help with other versions of autism disorder as well.
"Can we identify the core of what has to happen for someone to develop autism spectrum disorder? Can we prevent that in the future? The research that we've done is opening the door to those questions," Sznajder said.
_____
L.E. Baskow/Las Vegas Review-Journal/TNS L.E. Baskow
TNS
Copyright (C) 2025, Tribune Content Agency, LLC. Portions copyrighted by the respective providers.
This story was originally published May 6, 2025 at 4:04 AM.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Oklahoma AG signs letter critical of congressional efforts to prohibit AI state regulation
Oklahoma AG signs letter critical of congressional efforts to prohibit AI state regulation

Yahoo

time5 hours ago

  • Yahoo

Oklahoma AG signs letter critical of congressional efforts to prohibit AI state regulation

The entrance to the Oklahoma Attorney General's Office pictured on Tuesday, Feb. 25, 2025. (Photo by Janelle Stecklein/Oklahoma Voice) OKLAHOMA CITY – Oklahoma's attorney general is pushing back on a congressional effort to bar states from regulating artificial intelligence for the next decade. Attorney General Gentner Drummond is one of a bipartisan coalition of 40 attorneys general who signed a letter from the National Association of Attorneys General in opposition to an amendment in the One Big Beautiful Bill Act that bans state action on the issue. Drummond signed the letter opposing the Republican-led bill because there is no proposed federal regulatory framework to regulate artificial intelligence, said Leslie Berger, his spokesperson. 'Congress should not preclude states from enacting laws on the subject unless Congress itself enacts its own laws,' Berger said in a statement. 'The impact of such a broad moratorium would be sweeping and wholly destructive of reasonable state efforts to prevent known harms associated with AI,' according to the letter. States have passed their own regulations to address the harms associated with artificial intelligence such as prohibitions against AI-generated explicit materials, data privacy and protections for renters against using algorithms to establish rent, according to the letter. Oklahoma lawmakers have also launched efforts to regulate the growing use of artificial intelligence. House Bill 3453 attempts to define artificial intelligence and requires that Oklahomans be informed when they are interacting with AI. The bill passed out of the Oklahoma House, but stalled in the Senate. Lawmakers proposed other measures tackling AI usage include prohibiting spreading information using deepfake media within 90 days of an election and health care insurance providers, which would require insurers to disclose the use of AI based algorithms in their review process. They did not advance through the Senate. SUPPORT: YOU MAKE OUR WORK POSSIBLE SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX

Aarno Labs Awarded DARPA Grant to Develop Tools for Translating C to Safe Rust
Aarno Labs Awarded DARPA Grant to Develop Tools for Translating C to Safe Rust

Yahoo

time18 hours ago

  • Yahoo

Aarno Labs Awarded DARPA Grant to Develop Tools for Translating C to Safe Rust

Addressing the challenge of trusted, low-cost migration from C to Safe Rust for critical software systems BOSTON, MA / / June 9, 2025 / Aarno Labs, a research and development company focused on promoting high-assurance software via advanced program analysis and formal methods, has been selected by the Defense Advanced Research Projects Agency (DARPA) to develop advanced tools for translating legacy C code into safe, idiomatic Rust. The work is part of DARPA's newly launched TRACTOR program (Translating All C to Rust), which aims to eliminate memory safety vulnerabilities in critical software systems. The Aarno-led project, named Tenjin, will build a modular framework that combines source-level refactoring with multi-stage translation driven by comprehensive program understanding. The toolchain leverages Aarno's mature static and dynamic analysis platforms-CodeHawk and DIODE-to extract deep semantic models from C programs. These models enable the system to produce safe, maintainable Rust output, plus tests to validate the absence of introduced regressions. "C has been making computers vulnerable since before I was born," said Dr. Benjamin Karel, Principal Investigator at Aarno Labs. "Tenjin is designed to help maintainers of C codebases leave the past behind, producing functionally equivalent but safer Rust code." Aarno Labs is collaborating with researchers at the Massachusetts Institute of Technology (MIT), including Professors Michael Carbin and Martin Rinard, who bring deep expertise in programming languages, formal methods, and machine learning. The resulting tools will be released as open-source software intended to support public and private sector efforts to transition legacy code to memory-safe platforms. For more information, visit Name: Michael GordonEmail: info@ SOURCE: Aarno Labs, LLC View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Canadian Nuclear Laboratories and the University of Ottawa Accelerate Low Dose Radiation Research and Foster Next Generation of Scientists
Canadian Nuclear Laboratories and the University of Ottawa Accelerate Low Dose Radiation Research and Foster Next Generation of Scientists

Yahoo

time21 hours ago

  • Yahoo

Canadian Nuclear Laboratories and the University of Ottawa Accelerate Low Dose Radiation Research and Foster Next Generation of Scientists

New partnership furthers Canada's international leadership in low dose radiation research CANADIAN NUCLEAR LABORATORIES AND THE UNIVERSITY OF OTTAWA ACCELERATE LOW DOSE RADIATION RESEARCH AND FOSTER NEXT GENERATION OF SCIENTISTS CHALK RIVER, Ontario, June 09, 2025 (GLOBE NEWSWIRE) -- Canadian Nuclear Laboratories (CNL), Canada's premier nuclear science and technology organization, and the University of Ottawa (uOttawa), one of Canada's most innovative universities, are pleased to announce a new partnership to advance knowledge, education, research and innovation in low dose radiation (LDR) exposure health effects. Leveraging the leading research organizations' complementary capabilities, the new partnership builds on CNL's global leadership in LDR research with the establishment of a CNL-led LDR innovation hub, accelerating research critical to public safety and the health of Canadians. It will also serve to increase capabilities, education and training opportunities to graduate students and early career researchers. The partnership will also extend uOttawa researchers' access to Atomic Energy of Canada Limited's world class facilities at Chalk River Laboratories, including the unique Biological Research Facility, associated irradiation facilities and LDR Tissue Bank, and establishes a CNL satellite laboratory within uOttawa's new Advanced Medical Research Centre (AMRC) – set to open in 2026. This physical presence will be co-located with the Ottawa Institute of Systems Biology (OISB) as well as uOttawa state-of-the-art Core Facilities, which altogether will support new research directions in radiation sciences and advanced organoid-based systems biology. These areas are rapidly developing strengths at uOttawa, positioning the university as a national, and potentially international, leader in this field. uOttawa will also offer reciprocal access to key research facilities on campus, in addition to those located at the faculty of medicine and in AMRC. 'As a major player in the global research and development effort to support LDR research, CNL is focused on the prevention or reduction of radiation exposure effects in workers, patients and the larger population,' says Dr. Stephen Bushby, Vice-President, Science & Technology, CNL. 'We are very excited to include uOttawa as a major partner in the work needed to shed light on this complex field of research.' As part of this partnership, CNL will be contributing towards the acquisition of a mass spectrometer, which will be installed in the in the Metabolomics Core Facility at uOttawa. This strategic investment, supporting collaborative initiatives between OISB and CNL, will enable leading-edge single-cell metabolomics and spatial metabolomics, a rapidly advancing field with transformative potential in biomedical research. This will be the only equipment of its kind in eastern Canada, offering unique capabilities for high-resolution chemical imaging at the cellular level. The instrument will not only serve researchers at uOttawa, but also attract national and international collaborators, firmly establishing uOttawa as a leader in metabolomics and precision health research. The mass spectrometer will be a central component of the new Spatial Biology and Single-Cell Suite (3S) within the AMRC. This cutting-edge suite will integrate transformative new technologies into a coordinated workflow that complements and enhances five existing and intensively used Core Facilities: Flow Cytometry, Metabolomics, Gene Editing, Cellular Imaging, and Bioinformatics. By bridging these platforms, 3S will significantly expand research capabilities in some of uOttawa's strongest areas of discovery, particularly brain, heart, and cancer biology—driving breakthroughs in systems biology, precision medicine, and therapeutic development. 'This new equipment, the only one of its kind in Eastern Canada, positions the University of Ottawa as a leader in metabolomics and precision health research, while attracting national and international collaborations,' says Julie St-Pierre, Interim Vice-President, Research and Innovation, uOttawa. This new partnership builds on over a decade of collaborative research involving CNL and multiple uOttawa faculties, including Engineering, Science and Medicine. These collaborations have advanced understanding of the biomedical impacts of LDR, including studies on DNA damage and repair, protein synthesis, epigenetics, mitochondrial biology, metabolism, immunity, and stem cell functions. As part of this partnership, CNL has also provided funding support for postdoctoral fellow stipends, further enabling high-impact research and talent development. With the field of LDR research growing and Canadian leadership in LDR research well-recognized, both organizations will continue to explore additional opportunities to further strengthen this partnership. About CNL As Canada's premier nuclear science and technology laboratory and working under the direction of Atomic Energy of Canada Limited (AECL), CNL is a world leader in the development of innovative nuclear science and technology products and services. Guided by an ambitious corporate strategy known as Vision 2030, CNL fulfills three strategic priorities of national importance – restoring and protecting the environment, advancing clean energy technologies, and contributing to the health of Canadians. By leveraging the assets owned by AECL, CNL also serves as the nexus between government, the nuclear industry, the broader private sector and the academic community. CNL works in collaboration with these sectors to advance innovative Canadian products and services towards real-world use, including carbon-free energy, cancer treatments and other therapies, non-proliferation technologies and waste management solutions. To learn more about CNL, please visit About the University of Ottawa The University of Ottawa is powered by research. Located in Canada's capital, we bring together energetic and creative scholars to tackle urgent global challenges and to respond to emerging opportunities. As one of Canada's most innovative universities, we generate breakthroughs and discoveries that make a real difference in communities across Ontario, Canada and the world. Our thought leaders provide evidence-based insights that inform policy and support industry. Our influence keeps growing due to our vast range of international partnerships, including our membership in the U7+ Alliance. As the world's largest French-English university, we are a driving force in the Francophonie. To learn more about uOttawa, please visit CNL Contact:Philip KompassDirector, Corporate Communications1-866-886-2325media@ uOttawa contact:media@ A photo accompanying this announcement is available at

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store